A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia.
about
Synthetic lethality: emerging targets and opportunities in melanoma.Flexible CRISPR library construction using parallel oligonucleotide retrieval.sgRNA Scorer 2.0: A Species-Independent Model To Predict CRISPR/Cas9 Activity.Functional interrogation of non-coding DNA through CRISPR genome editing.Enhancing the genome editing toolbox: genome wide CRISPR arrayed librariesMolecular synergy underlies the co-occurrence patterns and phenotype of NPM1-mutant acute myeloid leukemia.Evaluation and Design of Genome-Wide CRISPR/SpCas9 Knockout Screens.Gene Essentiality Profiling Reveals Gene Networks and Synthetic Lethal Interactions with Oncogenic Ras.CRISPR-FOCUS: A web server for designing focused CRISPR screening experiments.Technical considerations for the use of CRISPR/Cas9 in hematology research.Optimised metrics for CRISPR-KO screens with second-generation gRNA libraries.CRISPR/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials.Pharmacologic Targeting of Chromatin Modulators As Therapeutics of Acute Myeloid LeukemiaA new target for differentiation therapy in AML.Constitutively Active SMAD2/3 Are Broad-Scope Potentiators of Transcription-Factor-Mediated Cellular Reprogramming.Dual direction CRISPR transcriptional regulation screening uncovers gene networks driving drug resistance.Inhibition of novel GCN5-ATM axis restricts the onset of acquired drug resistance in leukemia.Am I ready for CRISPR? A user's guide to genetic screens.Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer.CRISPR/Cas9 library screening for drug target discovery.Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control.Target Discovery for Precision Medicine Using High-Throughput Genome Engineering.Coupling shRNA screens with single-cell RNA-seq identifies a dual role for mTOR in reprogramming-induced senescence.CRISPR-Cas9 Genetic Analysis of Virus-Host Interactions.Single-cell whole exome and targeted sequencing in NPM1/FLT3 positive pediatric acute myeloid leukemia.PICKLES: the database of pooled in-vitro CRISPR knockout library essentiality screens.Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells.A High-Resolution Genome-Wide CRISPR/Cas9 Viability Screen Reveals Structural Features and Contextual Diversity of the Human Cell-Essential Proteome.Silencing of retrotransposons by SETDB1 inhibits the interferon response in acute myeloid leukemia.Mammalian Transcription Factor Networks: Recent Advances in Interrogating Biological Complexity.Generation of an arrayed CRISPR-Cas9 library targeting epigenetic regulators: from high-content screens to in vivo assays.CRISPR Approaches to Small Molecule Target Identification.A TFIID-SAGA Perturbation that Targets MYB and Suppresses Acute Myeloid Leukemia.Glutaminolysis is a metabolic dependency in FLT3ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition.A CRISPR-based screen for Hedgehog signaling provides insights into ciliary function and ciliopathies.Toward an integrated map of genetic interactions in cancer cells.Application of CRISPR-Cas9 Based Genome-Wide Screening Approaches to Study Cellular Signalling Mechanisms.LKB1, Salt-Inducible Kinases, and MEF2C Are Linked Dependencies in Acute Myeloid Leukemia.The chromatin-remodeling factor CHD4 is required for maintenance of childhood acute myeloid leukemia.Genome-wide CRISPR-Cas9 Screen Identifies Leukemia-Specific Dependence on a Pre-mRNA Metabolic Pathway Regulated by DCPS.
P2860
Q33578398-6D580E8A-79E0-46DA-A928-235F4BBF689FQ33879061-6479BF1B-E768-444E-995A-37BFC8B82E8DQ36266204-F9EA3FFA-8A7B-49F0-9040-C2E6AB3521A0Q36306820-1F0D0CD8-1718-4D01-A392-DB73B7335CAAQ36378294-5B9D7A82-ADA7-4C3E-9FC3-DC1B84142FC3Q38429500-ED250E77-7ECF-41C9-9DD8-6B5B4221B38BQ38706202-EEC85CC8-F073-4FDD-9AE1-4783A2FF7F40Q38717899-CEC15842-8508-479F-9435-795B124B8CACQ40066344-4CE6C97C-1B3E-4F77-91D5-2E505EDA39EEQ40113930-94781BC2-2CB5-40D7-9A5E-8354BB139F71Q41287841-B772EE76-1F11-466E-80C8-79AD6DF29D84Q42108657-FC84CD3E-032F-41A1-8097-2A21AD31C580Q42694670-11333486-9E80-4B5B-8436-CC0FDA0B74EFQ47124303-12BC4CB3-9BD0-4579-9BE5-81FA6D336C02Q47139123-409382FB-409D-4413-B314-A7A5286EEA41Q47148300-C4670D13-E12D-47D8-8188-B2D62F23D9A4Q47235241-77632D57-2B87-43E1-A74A-E114A23F6828Q47281660-01DE5152-6921-4EB7-AA11-E2B184FFE2EDQ47327040-63CD6683-C7F2-4747-BE95-BEFB34B07699Q47329392-24576170-1307-4938-BFBA-333CC83B39B5Q47352505-1AC5FB66-60FE-4CA6-B41B-6C6D9115C0E6Q47356354-00CCDF73-E529-4012-8616-9104A0A0874AQ47402261-B3DFBB9E-76CB-497D-A963-427A7040DD6DQ47547574-BE765BB3-344B-4D9F-A53B-E86114FF83ECQ47579484-06853666-07D1-413D-A85A-B02C21EA2D19Q47595090-6AD7BA2F-E62A-4815-92C9-F4CFF4E6A250Q47627028-39E032D0-BC8A-42A2-91B1-31405E6E6E6AQ47644126-C01D846E-B603-42AC-83A3-7DDDA910E57AQ47831063-967D7B00-F2FB-4D7D-A648-1A45CA6DBBB6Q47875614-DAD71650-1EB6-42C2-AB24-04E89F0ABF16Q48254888-BEE17090-F3B9-490C-9F76-B3436F22AC33Q48376848-92F1EA7C-F6B2-4396-BA60-7EAB8CCC5488Q48544889-7D725A06-126E-4DFA-9D23-1E157FBA105FQ49791801-BF5F67F4-9DF5-42CA-8117-1C502C24AACAQ49830782-6C46A317-1964-49C6-8A94-1431BEFF250EQ50308672-57FD4104-E7F4-4356-8B04-1E477C0F345BQ52347926-D11167D1-57E9-4134-8FCF-6BB70D4A4C28Q52430746-ADE633B4-A6C9-47EC-835F-D5DD60673279Q52431146-70EE427F-CD5B-40A0-BDCA-70631C71A6F9Q52686206-085D4AAC-41B3-41DD-BC71-ECC87E761225
P2860
A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia.
description
2016 nî lūn-bûn
@nan
2016 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
A CRISPR Dropout Screen Identi ...... ets in Acute Myeloid Leukemia.
@ast
A CRISPR Dropout Screen Identi ...... ets in Acute Myeloid Leukemia.
@en
A CRISPR Dropout Screen Identi ...... ets in Acute Myeloid Leukemia.
@nl
type
label
A CRISPR Dropout Screen Identi ...... ets in Acute Myeloid Leukemia.
@ast
A CRISPR Dropout Screen Identi ...... ets in Acute Myeloid Leukemia.
@en
A CRISPR Dropout Screen Identi ...... ets in Acute Myeloid Leukemia.
@nl
prefLabel
A CRISPR Dropout Screen Identi ...... ets in Acute Myeloid Leukemia.
@ast
A CRISPR Dropout Screen Identi ...... ets in Acute Myeloid Leukemia.
@en
A CRISPR Dropout Screen Identi ...... ets in Acute Myeloid Leukemia.
@nl
P2093
P2860
P50
P1433
P1476
A CRISPR Dropout Screen Identi ...... gets in Acute Myeloid Leukemia
@en
P2093
Ana Filipa Domingues
Annalisa Mupo
Emmanouil Metzakopian
Hannes Ponstingl
Hiroko Koike-Yusa
Jonathan Cooper
Kosuke Yusa
Malgorzata Gozdecka
P2860
P304
P356
10.1016/J.CELREP.2016.09.079
P50
P577
2016-10-01T00:00:00Z